Bringing the fundamentals into focus…
Back to Atrium Therapeutics, Inc.
How Atrium Therapeutics, Inc. stacks up
RNA · against 158 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #76 of 159 · scores higher than 37% of peers
Bars: peers in each 10-point band of the valuation score36 peers with a valuation score of 30–39, including RNA · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -62.4% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -37.9% vs peer median 0.0%
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
Metric by metric
Position: dot = RNA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 142 reported | -62.4% | -6.5% | 17% | 30% | |
| EBITDA yieldHigher is better · 167 reported | 55.0% | 1.8% | 93% | 50% | |
| Free cash flow yieldHigher is better · 108 reported | -37.9% | -14.4% | 28% | 20% | |
| Book yieldHigher is better · 145 reported | 143.9% | 72.3% | 82% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around RNA| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 76 | 239M USD | 33 | 38 | |
| 76 | 110M USD | 33 | 54 | |
| 76 | 117M USD | 33 | 40 | |
| 76 | 276M USD | 33 | 46 | |
| 76 | 149M USD | 33 | ||
| 76 | 191M USD | 33 | 38 | |
| 76 | 165M USD | 33 | 50 | |
| 76 | 158M USD | 33 | 14 | |
| 76 | 142M USD | 33 | 45 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score